Cargando…
Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests—A Population-Based Evaluation
Antibody testing for determining the SARS-CoV-2 serostatus was rapidly introduced in early 2020 and since then has been gaining special emphasis regarding correlates of protection. With limited access to representative samples with known SARS-CoV-2 infection status during the initial period of test...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534748/ https://www.ncbi.nlm.nih.gov/pubmed/34679541 http://dx.doi.org/10.3390/diagnostics11101843 |
_version_ | 1784587619254927360 |
---|---|
author | Einhauser, Sebastian Peterhoff, David Niller, Hans Helmut Beileke, Stephanie Günther, Felix Steininger, Philipp Burkhardt, Ralph Heid, Iris M. Pfahlberg, Annette B. Überla, Klaus Gefeller, Olaf Wagner, Ralf |
author_facet | Einhauser, Sebastian Peterhoff, David Niller, Hans Helmut Beileke, Stephanie Günther, Felix Steininger, Philipp Burkhardt, Ralph Heid, Iris M. Pfahlberg, Annette B. Überla, Klaus Gefeller, Olaf Wagner, Ralf |
author_sort | Einhauser, Sebastian |
collection | PubMed |
description | Antibody testing for determining the SARS-CoV-2 serostatus was rapidly introduced in early 2020 and since then has been gaining special emphasis regarding correlates of protection. With limited access to representative samples with known SARS-CoV-2 infection status during the initial period of test development and validation, spectrum bias has to be considered when moving from a “test establishment setting” to population-based settings, in which antibody testing is currently implemented. To provide insights into the presence and magnitude of spectrum bias and to estimate performance measures of antibody testing in a population-based environment, we compared SARS-CoV-2 neutralization to a battery of serological tests and latent class analyses (LCA) in a subgroup (n = 856) of the larger population based TiKoCo-19 cohort (n = 4185). Regarding spectrum bias, we could proof notable differences in test sensitivities and specificities when moving to a population-based setting, with larger effects visible in earlier registered tests. While in the population-based setting the two Roche ELECSYS anti-SARS-CoV-2 tests outperformed every other test and even LCA regarding sensitivity and specificity in dichotomous testing, they didn’t provide satisfying quantitative correlation with neutralization capacity. In contrast, our in-house anti SARS-CoV-2-Spike receptor binding domain (RBD) IgG-ELISA (enzyme-linked-immunosorbant assay) though inferior in dichotomous testing, provided satisfactory quantitative correlation and may thus represent a better correlate of protection. In summary, all tests, led by the two Roche tests, provided sufficient accuracy for dichotomous identification of neutralizing sera, with increasing spectrum bias visible in earlier registered tests, while the majority of tests, except the RBD-ELISA, didn’t provide satisfactory quantitative correlations. |
format | Online Article Text |
id | pubmed-8534748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85347482021-10-23 Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests—A Population-Based Evaluation Einhauser, Sebastian Peterhoff, David Niller, Hans Helmut Beileke, Stephanie Günther, Felix Steininger, Philipp Burkhardt, Ralph Heid, Iris M. Pfahlberg, Annette B. Überla, Klaus Gefeller, Olaf Wagner, Ralf Diagnostics (Basel) Article Antibody testing for determining the SARS-CoV-2 serostatus was rapidly introduced in early 2020 and since then has been gaining special emphasis regarding correlates of protection. With limited access to representative samples with known SARS-CoV-2 infection status during the initial period of test development and validation, spectrum bias has to be considered when moving from a “test establishment setting” to population-based settings, in which antibody testing is currently implemented. To provide insights into the presence and magnitude of spectrum bias and to estimate performance measures of antibody testing in a population-based environment, we compared SARS-CoV-2 neutralization to a battery of serological tests and latent class analyses (LCA) in a subgroup (n = 856) of the larger population based TiKoCo-19 cohort (n = 4185). Regarding spectrum bias, we could proof notable differences in test sensitivities and specificities when moving to a population-based setting, with larger effects visible in earlier registered tests. While in the population-based setting the two Roche ELECSYS anti-SARS-CoV-2 tests outperformed every other test and even LCA regarding sensitivity and specificity in dichotomous testing, they didn’t provide satisfying quantitative correlation with neutralization capacity. In contrast, our in-house anti SARS-CoV-2-Spike receptor binding domain (RBD) IgG-ELISA (enzyme-linked-immunosorbant assay) though inferior in dichotomous testing, provided satisfactory quantitative correlation and may thus represent a better correlate of protection. In summary, all tests, led by the two Roche tests, provided sufficient accuracy for dichotomous identification of neutralizing sera, with increasing spectrum bias visible in earlier registered tests, while the majority of tests, except the RBD-ELISA, didn’t provide satisfactory quantitative correlations. MDPI 2021-10-06 /pmc/articles/PMC8534748/ /pubmed/34679541 http://dx.doi.org/10.3390/diagnostics11101843 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Einhauser, Sebastian Peterhoff, David Niller, Hans Helmut Beileke, Stephanie Günther, Felix Steininger, Philipp Burkhardt, Ralph Heid, Iris M. Pfahlberg, Annette B. Überla, Klaus Gefeller, Olaf Wagner, Ralf Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests—A Population-Based Evaluation |
title | Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests—A Population-Based Evaluation |
title_full | Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests—A Population-Based Evaluation |
title_fullStr | Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests—A Population-Based Evaluation |
title_full_unstemmed | Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests—A Population-Based Evaluation |
title_short | Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests—A Population-Based Evaluation |
title_sort | spectrum bias and individual strengths of sars-cov-2 serological tests—a population-based evaluation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534748/ https://www.ncbi.nlm.nih.gov/pubmed/34679541 http://dx.doi.org/10.3390/diagnostics11101843 |
work_keys_str_mv | AT einhausersebastian spectrumbiasandindividualstrengthsofsarscov2serologicaltestsapopulationbasedevaluation AT peterhoffdavid spectrumbiasandindividualstrengthsofsarscov2serologicaltestsapopulationbasedevaluation AT nillerhanshelmut spectrumbiasandindividualstrengthsofsarscov2serologicaltestsapopulationbasedevaluation AT beilekestephanie spectrumbiasandindividualstrengthsofsarscov2serologicaltestsapopulationbasedevaluation AT guntherfelix spectrumbiasandindividualstrengthsofsarscov2serologicaltestsapopulationbasedevaluation AT steiningerphilipp spectrumbiasandindividualstrengthsofsarscov2serologicaltestsapopulationbasedevaluation AT burkhardtralph spectrumbiasandindividualstrengthsofsarscov2serologicaltestsapopulationbasedevaluation AT heidirism spectrumbiasandindividualstrengthsofsarscov2serologicaltestsapopulationbasedevaluation AT pfahlbergannetteb spectrumbiasandindividualstrengthsofsarscov2serologicaltestsapopulationbasedevaluation AT uberlaklaus spectrumbiasandindividualstrengthsofsarscov2serologicaltestsapopulationbasedevaluation AT gefellerolaf spectrumbiasandindividualstrengthsofsarscov2serologicaltestsapopulationbasedevaluation AT wagnerralf spectrumbiasandindividualstrengthsofsarscov2serologicaltestsapopulationbasedevaluation |